The US Food and Drug Administration (FDA) classifies biomarkers into diagnostic, monitoring, response, predictive, prognostic, safety, and susceptibility/risk biomarkers and reasonably likely surrogate endpoints (FDA 2016). For voice biomarkers, what is important is their use as diagnostic, monitoring, or response biomarkers. In other words, voice-based screening can be used to detect (diagnose) diseases at an early stage, monitor disease progression and remission, and confirm the response to and efficacy of drug therapies and other interventions.